(2Z)-1-methyl-2-[(Z)-3-(1-methylquinolin-1-ium-2-yl)prop-2-enylidene]quinoline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (2Z)-1-methyl-2-[(Z)-3-(1-methylquinolin-1-ium-2-yl)prop-2-enylidene]quinoline
• 化学式: C23H21N2+
• 分子量: 325.4
• InChiKey: HHAICMDCZBDVDL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  7.1
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• CANCER CELL INHIBITORY DRUG AND CANCER STEM-CELL DETECTION PROBE
  申请人：CANON KABUSHIKI KAISHA

  公开号：US20150182518A1

  公开（公告）日：2015-07-02

  An object of the present invention is to provide a cancer cell inhibitory drug, particularly a cancer stem-cell inhibitory drug, or a cancer stem-cell detection probe. The present invention provides a cancer cell inhibitory drug comprising at least one compound represented by general formula (1) as an active ingredient.
• METHOD OF DETECTING CANCER STEM CELL, METHOD OF SCREENING CANCER STEM CELL, AND METHOD OF INHIBITING CANCER STEM CELL
  申请人：CANON KABUSHIKI KAISHA

  公开号：US20170340622A1

  公开（公告）日：2017-11-30

  An object of the present invention is to provide a cancer cell inhibitory drug, particularly a cancer stem-cell inhibitory drug, or a cancer stem-cell detection probe. The present invention provides a cancer cell inhibitory drug comprising at least one compound represented by general formula (1) as an active ingredient
• [EN] DIQUINOLONIUM SALT FOR THE TREATMENT OF CANCER<br/>[FR] SEL DE DIQUINOLONIUM DESTINÉ AU TRAITEMENT DU CANCER
  申请人：UNIV HEALTH NETWORK

  公开号：WO2009109029A1

  公开（公告）日：2009-09-11

  The application provides a novel treatment for a cancer, including for a hematological malignancy and/or a solid tumor using a pharmaceutically acceptable salt of a 1-methyl-2-[3-(1-methyl-1,2-dihydroquinolin-2-yliden)prop-1-enyl]quinolinium cation.
• [EN] AUTOPHAGY-INDUCING MOLECULES FOR INCREASING INSULIN RELEASE<br/>[FR] MOLÉCULES INDUISANT UNE AUTOPHAGIE PERMETTANT D'AUGMENTER LA LIBÉRATION D'INSULINE
  申请人：UNIV STRASBOURG

  公开号：WO2016119856A1

  公开（公告）日：2016-08-04

  The present invention relates to the use of autophagy-inducing molecules for increasing release or secretion of insulin by pancreatic β cells. It is useful for treating hyperglycemia, associated or not with diabetes.